These results indicated that TGFBR3 is a tumor suppressor in oral cancer and that GIPC1 and ARRB2, both of which interact with the cytoplasmic domain of TGFBR3, differentially mediate TGFBR3 anti-cancer activity (Figure 8). Here, ARRB2 is linked to lip and oral cavity carcinoma.